Omalizumab for Injection

Omalizumab is a humanized monoclonal antibody of human immunoglobulin E produced by Chinese hamster ovary cells using gene recombination technology. It can be used to treat allergic asthma and chronic spontaneous urticaria.
Allergic asthma: Omalizumab is suitable for the treatment of patients with confirmed (immunoglobulin E)-mediated asthma. It is suitable for adults, adolescents (12 years and above) and children (6 to 12 years old) for moderate to severe persistent allergic asthma whose symptoms cannot be effectively controlled after treatment with inhaled corticosteroids and long-acting inhaled β2-adrenergic receptor agonists. It can reduce the asthma exacerbation rate of these patients.
Chronic spontaneous urticaria: It is suitable for adults and adolescents (12 years and above) with chronic spontaneous urticaria who still have symptoms after treatment with H1 antihistamines.